Coverage Afternoon Session on Precision Oncology: Advancing Precision Medicine Annual Conference, Philadelphia PA November 1 2024
Reporter: Stephen J. Williams, Ph.D.
Unlocking the Next Quantum Leap in Precision Medicine – A Town Hall Discussion (CME Eligible)
Co-Chairs
Amanda Paulovich, Professor, Aven Foundation Endowed Chair
Fred Hutchinson Cancer Center
Susan Monarezm Deputy Director ARPA-H
Henry Rodriguez, NCI/NIH
Eric Schadt, Pathos
Ezra Cohen, Tempus
Jennifer Leib, Innovation Policy Solutions
Nick Seddon, Optum Genomics
Giselle Sholler, Penn State Hershey Children’s Hospital
Janet Woodcock, formerly FDA
Amanda Paulovich: Frustrated by the variability in cancer therapy results. Decided to help improve cancer diagnostics
- We have plateaued on relying on single gene single protein companion diagnostics
- She considers that regulatory, economic, and cultural factors are hindering the innovation and resulting in the science way ahead of the clinical aspect of diagnostics
- Diagnostic research is not as well funded as drug discovery
- Biomarkers, the foundation for the new personalized medicine, should be at forefront Read the Tipping Point by Malcolm Gladwell
- FDA is constrained by statutory mandates
Eric Schadt
Pathos
- Multiple companies trying to chase different components of precision medicine strategy including all the one involved in AI
- He is helping companies creating those mindmaps, knowledge graphs, and create more predictive systems
- Population screening into population groups will be using high dimensional genomic data to determine risk in various population groups however 60% of genomic data has no reported ancestry
- He founded Sema4 but many of these companies are losing $$ on these genomic diagnostics
- So the market is not monetizing properly
- Barriers to progress: arbitrary evidence thresholds for payers, big variation across health care system, regulatory framework
Beat Childhood Cancer Consortium Giselle
- Consortium of university doctors in pediatrics
- They had a molecular tumor board to look at the omics data
- Showed example of choroid plexus tumor success with multi precision meds vs std chemo
- Challenges: understanding differences in genomics test (WES, NGS, transcriptome etc.
- Precision medicine needs to be incorporated in med education.. Fellowships.. Residency
- She spends hours with the insurance companies providing more and more evidence to justify reimbursements
- She says getting that evidence is a challenged; biomedical information needs to be better CURATED
Dr. Ezra Cohen, Tempest
- HPV head and neck cancer, good prognosis, can use cituximab and radiation
- $2 billion investment at Templest of AI driven algorithm to integrate all omics; used LLM models too
Dr. Janet Woodcock
- Our theoretical problem with precision and personalized medicine is that we are trained to think of the average patient
- ISPAT II trial a baysian trial; COVID was a platform trial
- She said there should there be NIH sponsored trials on adaptive biomarker platform trials
This event will be covered by the LPBI Group on Twitter. Follow on
using the following meeting hashtags
2012pharmaceutical
sjwilliamspa
Leave a Reply